Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Debra Ainge

- PMLiVE

Bristol Myers Squibb granted EC approval for Breyanzi in follicular lymphoma

The disease accounts for up to 30% of non-Hodgkin lymphoma cases

- PMLiVE

Roche to launch new innovation centre at Harvard’s Enterprise Research Campus

The first phase of construction on the ERC is expected to be complete in 2026

- PMLiVE

Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study

Regulatory submissions are expected to be complete in the first half of this year

- PMLiVE

2025 PM Society Awards – winners announced

21GRAMS and Havas Lynx win big; AstraZeneca and UCB top client leader board

- PMLiVE

FREE WEBINAR – Not Just a Number: Making Sure Every Voice Shapes the Future of Medicine – Origins & ISPEP

What Does Patient-focused Healthcare Really Mean? Healthcare is built around patients, but too often, their voices are an afterthought. Truly patient-focused medicine isn’t just about treatment - it’s about understanding...

Origins – The Patient Focused Specialists

- PMLiVE

Prime minister unveils UK government’s plans to abolish NHS England

The move aims to cut waiting times and free up money for front-line services

- PMLiVE

AstraZeneca/Ionis’ Wainzua granted EC approval to treat rare disease ATTRv-PN

ATTRv with polyneuropathy affects up to 40,000 people worldwide

- PMLiVE

DSRU appoints Linda Härmark as director

Härmark is currently deputy director at the Netherlands Pharmacovigilance Centre Lareb

- PMLiVE

NEW WEBINAR! From Clicks to Outcomes: Measuring the Impact of Your Medical Education Platform

Struggling to quantify the value of your medical education platform and prove its ROI? Join our upcoming Pharma-exclusive webinar to learn real-work strategies and tips for developing a Med Ed...

Impetus Digital

- PMLiVE

World Kidney Day – Boehringer launches CKD initiative to tackle UK health inequalities

Approximately 10% of the UK population is affected by chronic kidney disease

Biogen Idec building

Biogen initiates phase 3 study of felzartamab in kidney transplant patients

The trial will evaluate the candidate in patients with antibody-mediated rejection

- PMLiVE

NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

Around 1,000 patients could benefit from the relugolix combination therapy every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links